We hypothesized that MYXV∆SERP2’s oncolytic effects could be improved by pre-treating canine STS patients with oclacitinib to suppress the anti-viral IFN immune response before MYXVΔSERP2 was administered. Here, IFNA1 is linked to telomere syndrome.